BCTX
BriaCell Therapeutics Corp.
Next earnings Oct 14, 2026 (after close)
$3.06
▲ +3.03%$3.06▼ -90.00%
over 1Y
L $2.74EODHDH $31.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+1.7%
1M-15.7%
3M-18.4%
YTD-57.3%
1Y-90.0%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 5 analysts
Buy
Mixed signals in the latest filings.
BriaCell Therapeutics Corp. shows limited reported revenue, and -151.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$6.98M | -$15.3M | -$23.3M | -$33.3M | -$27.2M |
| Net income | -$13.8M | -$26.8M | -$20.3M | -$4.79M | -$26.3M |
| Diluted EPS | — | -$1.73 | -$1.30 | -$43.68 | -$62.19 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$4.73M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-456.4%
FCF yield-496.6%
Quality & risk
ROIC (est.)-124.0%
Free cash flow-$28.6M
Total debt—
Net cash$10.5M
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-94.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-262026-06-26open ↗10-QPeriod ending 2026-04-302026-06-09open ↗8-KPeriod ending 2026-05-312026-06-03open ↗424B5Filing2026-06-02open ↗8-KPeriod ending 2026-03-312026-03-31open ↗10-QPeriod ending 2026-01-312026-03-10open ↗8-KPeriod ending 2026-03-052026-03-09open ↗25-NSEFiling2026-02-26open ↗8-KPeriod ending 2026-02-182026-02-20open ↗DEF 14APeriod ending 2026-02-122026-02-12open ↗SCHEDULE 13GFiling2026-01-23open ↗8-KPeriod ending 2026-01-132026-01-15open ↗
Frequently asked
- Is BriaCell Therapeutics Corp. (BCTX) a buy?
- BCTX currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is BriaCell Therapeutics Corp.'s quality score?
- BCTX scores 32.07692307692308/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001610820, latest 10-Q filed 2026-06-09) · EODHD · as of 6/26/2026, 7:43:03 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.